[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK1401828T3 - N-Formylhydroxylaminforbindelser som inhibitorer af PDF - Google Patents

N-Formylhydroxylaminforbindelser som inhibitorer af PDF

Info

Publication number
DK1401828T3
DK1401828T3 DK02754681T DK02754681T DK1401828T3 DK 1401828 T3 DK1401828 T3 DK 1401828T3 DK 02754681 T DK02754681 T DK 02754681T DK 02754681 T DK02754681 T DK 02754681T DK 1401828 T3 DK1401828 T3 DK 1401828T3
Authority
DK
Denmark
Prior art keywords
pdf
inhibitors
formylhydroxylamine
compounds
formylhydroxylamine compounds
Prior art date
Application number
DK02754681T
Other languages
English (en)
Inventor
Dinesh V Patel
Rakesh K Jain
Alvarez Salvador Garcia
Zhengyu Yuan
Jeffrey Jacobs
Original Assignee
Vicuron Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vicuron Pharm Inc filed Critical Vicuron Pharm Inc
Application granted granted Critical
Publication of DK1401828T3 publication Critical patent/DK1401828T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK02754681T 2001-06-15 2002-06-14 N-Formylhydroxylaminforbindelser som inhibitorer af PDF DK1401828T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29841901P 2001-06-15 2001-06-15
US36031302P 2002-02-27 2002-02-27

Publications (1)

Publication Number Publication Date
DK1401828T3 true DK1401828T3 (da) 2006-07-31

Family

ID=26970649

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02754681T DK1401828T3 (da) 2001-06-15 2002-06-14 N-Formylhydroxylaminforbindelser som inhibitorer af PDF

Country Status (31)

Country Link
US (1) US7148242B2 (da)
EP (1) EP1401828B1 (da)
JP (1) JP4361365B2 (da)
KR (2) KR20060014083A (da)
CN (1) CN1511152A (da)
AR (1) AR036053A1 (da)
AT (1) ATE323081T1 (da)
AU (1) AU2002321062B2 (da)
BR (1) BR0210377A (da)
CA (1) CA2448526A1 (da)
CO (1) CO5640131A2 (da)
CY (1) CY1105085T1 (da)
CZ (1) CZ20033388A3 (da)
DE (1) DE60210612T2 (da)
DK (1) DK1401828T3 (da)
ES (1) ES2262824T3 (da)
HK (1) HK1064370A1 (da)
HU (1) HUP0400208A3 (da)
IL (1) IL158770A0 (da)
MX (1) MXPA03011628A (da)
MY (1) MY138619A (da)
NO (1) NO327420B1 (da)
NZ (1) NZ529489A (da)
PE (1) PE20030100A1 (da)
PL (1) PL364476A1 (da)
PT (1) PT1401828E (da)
RU (1) RU2325386C2 (da)
SI (1) SI1401828T1 (da)
SK (1) SK15242003A3 (da)
WO (1) WO2002102790A1 (da)
ZA (1) ZA200308379B (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE360014T1 (de) * 2001-06-15 2007-05-15 Vicuron Pharm Inc Bicyclische pyrrolidinverbindungen
GB0208579D0 (en) * 2002-04-13 2002-05-22 British Biotech Pharm Antibacterial agents
ES2321504T3 (es) 2002-09-19 2009-06-08 Novartis Ag Proceso para la preparacion de productos intermedios.
JP2006519786A (ja) * 2003-02-21 2006-08-31 ノバルティス アクチエンゲゼルシャフト Ｎ−ホルミルヒドロキシルアミン化合物を得るための中間体作成に関する化学的方法
TW200427458A (en) * 2003-04-02 2004-12-16 Novartis Ag Crystalline N-formyl hydroxylamine compounds
MXPA05014217A (es) * 2003-06-26 2006-03-09 Novartis Ag Proceso para preparar intermediarios utiles para preparar ciertas n-formil hidroxilaminas antibacterianas.
KR100527624B1 (ko) * 2003-08-21 2005-11-22 한기종 질소에 포밀기를 갖는 아민유도체의 새로운 제조방법
AU2005259488B2 (en) * 2004-06-30 2009-10-01 Novartis Ag Method for increasing the susceptibility of peptide deformylase inhibitors by using efflux pump inhibitors
WO2006055663A2 (en) 2004-11-17 2006-05-26 Smithkline Beecham Corporation The use of novel antibacterial compounds
GT200600196A (es) * 2005-05-23 2007-01-15 Compuestos n-formil de hidroxilamina
DE102005026231A1 (de) * 2005-06-07 2006-12-14 Origenis Ag Peptid-Deformylase (PDF) Inhibitoren 3
CA2610304A1 (en) * 2005-06-07 2006-12-14 Novartis Ag Peptide deformylase (pdf) inhibitors 4
SG133452A1 (en) * 2005-12-30 2007-07-30 Novartis Ag Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases
EP1994027A2 (en) * 2006-03-03 2008-11-26 Novartis AG N-formyl hydroxylamine compounds
CN101328155B (zh) * 2007-06-20 2010-11-03 上海医药工业研究院 噁唑烷衍生物及其制备方法和应用
CN101434570B (zh) * 2007-11-16 2011-02-02 上海医药工业研究院 吡咯烷衍生物及其制备方法和应用
CN101584694B (zh) * 2009-06-15 2011-01-12 华东师范大学 含2,5-二氢吡咯的肽脱甲酰基酶抑制剂及合成方法
KR20120049940A (ko) * 2009-09-04 2012-05-17 노파르티스 아게 키나제 억제제로서의 헤테로아릴 화합물
BR112012022511A2 (pt) * 2010-03-10 2016-08-30 Ingenium Pharmaceuticals Gmbh inibidores de proteína quinases
JP5825086B2 (ja) 2011-12-19 2015-12-02 住友化学株式会社 α−置換−β−アミノ酸エステル誘導体不斉加水分解酵素
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
WO2016164580A1 (en) 2015-04-07 2016-10-13 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
ES2930814T3 (es) * 2016-05-11 2022-12-22 Guangdong Hebo Pharmaceutical Co Ltd Inhibidor de péptido deformilasa de anillo espiro de tres miembros o anillo espiro de cinco miembros y uso del mismo como agente antitumoral

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4052511A (en) 1976-02-13 1977-10-04 E. R. Squibb & Sons, Inc. Carboxyacylproline derivatives
US4311705A (en) 1980-10-06 1982-01-19 E. R. Squibb & Sons, Inc. Carboxyalkanoyl and hydroxycarbamoylalkanoyl derivatives of substituted prolines
US4321383A (en) 1980-11-24 1982-03-23 E. R. Squibb & Sons, Inc. Heterobicyclo intermediates
US4303662A (en) 1980-11-24 1981-12-01 E. R. Squibb & Sons, Inc. Carboxyacyl, mercapto and acylmercapto derivatives of heterobicyclo compounds
JPS6188884A (ja) 1984-10-04 1986-05-07 Sankyo Co Ltd エンケフアリナ−ゼｂ阻害物質およびその製法
US4599361A (en) 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
DK77487A (da) 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
FR2609289B1 (fr) 1987-01-06 1991-03-29 Bellon Labor Sa Roger Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes
US5128346A (en) 1987-09-21 1992-07-07 Abbott Laboratories Derivatives of D-glutamic acid and D-aspartic acid
EP0334244A3 (en) 1988-03-25 1991-05-29 The Procter & Gamble Company Bradykinin antagonist peptides
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
GB8827308D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
GB8919251D0 (en) 1989-08-24 1989-10-04 British Bio Technology Compounds
GB8921326D0 (en) 1989-09-21 1989-11-08 Beecham Group Plc Novel treatment
US5268384A (en) 1990-11-21 1993-12-07 Galardy Richard E Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
WO1992009565A1 (en) 1990-12-03 1992-06-11 Celltech Limited Peptidyl derivatives
CA2058797A1 (en) 1991-02-01 1992-08-02 Michael John Broadhurst Amino acid derivatives
GB9102635D0 (en) 1991-02-07 1991-03-27 British Bio Technology Compounds
IT1245712B (it) 1991-04-09 1994-10-14 Boehringer Mannheim Italia Ammine eterocicliche utili terapia dell'asma e dell'infiammazione delle vie aeree
WO1992022523A2 (en) 1991-06-14 1992-12-23 Research Corporation Technologies, Inc. Peptide derivatives of collagenase inhibitor
US5256657A (en) 1991-08-19 1993-10-26 Sterling Winthrop, Inc. Succinamide derivative matrix-metalloprotease inhibitors
JPH05125029A (ja) 1991-11-06 1993-05-21 Yamanouchi Pharmaceut Co Ltd 新規なアミド化合物又はその塩
KR100255203B1 (ko) 1991-11-08 2000-05-01 가와무라 요시부미 콜라게나제 저해제
DE69309047T2 (de) 1992-04-07 1997-09-11 British Biotech Pharm Hydroxamsäure enthaltende collagenase-inhibitoren und cytokinaktivitätsinhibitoren
GB9211707D0 (en) 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
GB9211706D0 (en) 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
US5318964A (en) 1992-06-11 1994-06-07 Hoffmann-La Roche Inc. Hydroxamic derivatives and pharmaceutical compositions
GB9215665D0 (en) 1992-07-23 1992-09-09 British Bio Technology Compounds
US5552419A (en) 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
CA2136108A1 (en) 1993-03-18 1994-09-29 Makoto Sakamoto Carbostyril derivatives as matrix metalloproteinases inhibitors
EP0648205B1 (en) 1993-04-27 1999-07-14 Celltech Therapeutics Limited Peptidyl derivatives as metalloproteinase inhibitors
GB9308695D0 (en) 1993-04-27 1993-06-09 Celltech Ltd Peptidyl derivatives
GB9501737D0 (en) 1994-04-25 1995-03-22 Hoffmann La Roche Hydroxamic acid derivatives
GB9411598D0 (en) 1994-06-09 1994-08-03 Hoffmann La Roche Hydroxamic acid derivatives
GB9502858D0 (en) 1995-02-14 1995-04-05 British Biotech Pharm Novel use of matrix metalloproteinase inhibitors
GB9504084D0 (en) 1995-03-01 1995-04-19 British Biotech Pharm Synthesis of carboxylic and hydroxamic acid derivatives
FR2733750B1 (fr) 1995-05-03 1997-06-13 Synthelabo Derives de l'acide gamma-oxo-alpha-(phenylmethyl)-5,6- dihydro-4h-thieno(3,4-c)pyrrole-5-butanoique, leur preparation et leur application en therapeutique
EP0939632B1 (en) 1996-02-23 2005-10-05 Eli Lilly And Company NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS
TW448172B (en) 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
GB9613547D0 (en) 1996-06-27 1996-08-28 Pharmacia Spa Matrix metalloproteinase inhibitors
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
CA2265671A1 (en) 1997-07-10 1999-01-21 Daniela Jabes Matrix metalloproteinase inhibitors
CA2320476A1 (en) * 1998-02-07 1999-08-12 British Biotech Pharmaceuticals Limited Antibacterial agents

Also Published As

Publication number Publication date
ZA200308379B (en) 2004-05-21
CZ20033388A3 (en) 2004-03-17
WO2002102790A1 (en) 2002-12-27
HK1064370A1 (en) 2005-01-28
DE60210612D1 (de) 2006-05-24
HUP0400208A3 (en) 2008-10-28
PL364476A1 (en) 2004-12-13
CN1511152A (zh) 2004-07-07
SK15242003A3 (sk) 2004-07-07
EP1401828A1 (en) 2004-03-31
IL158770A0 (en) 2004-05-12
JP4361365B2 (ja) 2009-11-11
MXPA03011628A (es) 2005-03-07
ES2262824T3 (es) 2006-12-01
NZ529489A (en) 2005-10-28
CY1105085T1 (el) 2009-11-04
NO327420B1 (no) 2009-06-29
KR20060014083A (ko) 2006-02-14
PE20030100A1 (es) 2003-03-28
ATE323081T1 (de) 2006-04-15
HUP0400208A2 (hu) 2004-06-28
KR20040010721A (ko) 2004-01-31
PT1401828E (pt) 2006-08-31
BR0210377A (pt) 2004-08-10
AR036053A1 (es) 2004-08-04
NO20035571D0 (no) 2003-12-12
NO20035571L (no) 2004-02-16
RU2003137565A (ru) 2005-05-27
CA2448526A1 (en) 2002-12-27
DE60210612T2 (de) 2006-09-21
RU2325386C2 (ru) 2008-05-27
MY138619A (en) 2009-07-31
US20030045479A1 (en) 2003-03-06
US7148242B2 (en) 2006-12-12
KR100589544B1 (ko) 2006-06-15
AU2002321062B2 (en) 2006-02-02
EP1401828B1 (en) 2006-04-12
JP2005502606A (ja) 2005-01-27
SI1401828T1 (sl) 2006-10-31
CO5640131A2 (es) 2006-05-31

Similar Documents

Publication Publication Date Title
DK1401828T3 (da) N-Formylhydroxylaminforbindelser som inhibitorer af PDF
DK1463506T3 (da) Substituerede quinazolin-derivater som inhibitorer af aurora-kinaser
DK1438306T3 (da) Derivater af UK-2A
DK1562589T3 (da) Diaminotriazoler der er nyttige som inhibitorer af proteinkinaser
DK1360169T3 (da) Succinatsalt af O-desmethyl-venlafaxin
NO20033593L (no) Kinazoliner som MMP-13 inhibitorer
DK1611112T3 (da) Isoxazolforbindelser som hæmmere af varmechokproteiner
DK1532138T3 (da) Inhibitorer af tyrosinkinaser
DK1664043T3 (da) Sammensætninger egnede som inhibitorer af proteinkinaser
DK1581515T3 (da) Triazolderivater som inhibitorer af 11-beta-hydroxysteroid-dehydrogenase-1
ATE294805T1 (de) Triazoloverbindungen als mmp-inhibitoren
DK1417180T3 (da) Fremstilling af aminopyrimidinforbindelser
IS6971A (is) Ný efnasambönd
DK1542977T3 (da) 2,5-dioxoimidazolidin-4-ylacetamider og analoger som inhibitorer af metalloproteinase MMP12
NO20041887L (no) Benzomidazoler anvendelige som proteinkinase-inhibitorer
NO20033618L (no) Ftalayinon-piperidino-derivater som PDE-4-inhibitorer
IS7287A (is) Pýrimídín efnasambönd
DK1840125T3 (da) Mellemprodukter til fremstilling af dioxan-2-alkylcarbamater
DK1660090T3 (da) Quinazolin-analoger som receptor-tyrosinkinase-inhibitorer
IS6868A (is) Ný pýrimidínefnasambönd
DK1516540T3 (da) Anvendelse af vitamin D-forbindelser
DK1536796T3 (da) N-arylpiperidinsubstituerede biphenylcarboxamider som inhibitorer af apolipoprotein B-sektion
DK1600441T3 (da) Krystallinsk form af elrcanidipinhydrochlorid til anvendelse som et antihypertensivt middel
DK1892239T3 (da) Inhibitorer af cytosol-phospholipase A2
DK1353923T3 (da) Forbedret fremgangsmåde til syntese af carbapenem